Vaccine

Unity Consortium Kicks Off Adolescent Immunization Action Week (AIAW25) to Help Parents and Adolescents Stay on TASK with Recommended ImmunizationsUnity Consortium Kicks Off Adolescent Immunization Action Week (AIAW25) to Help Parents and Adolescents Stay on TASK with Recommended Immunizations

Unity Consortium Kicks Off Adolescent Immunization Action Week (AIAW25) to Help Parents and Adolescents Stay on TASK with Recommended Immunizations

Stay on TASK Infographic Infographic describing the four steps to being able to get vaccinated with confidence described by TASK…

2 months ago
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma PatientsCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of…

2 months ago
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient IdentificationBrii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients…

2 months ago
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company ProgressHilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for…

2 months ago
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitorsPress Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia…

2 months ago
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDPress Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

  Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU,…

2 months ago
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateAIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer…

2 months ago
Evaxion to announce business update and full year 2024 financial results on April 1, 2025Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…

2 months ago
Prime Biome Reviews Controversy Disclosure Report: Surprising Facts and Figures RevealedPrime Biome Reviews Controversy Disclosure Report: Surprising Facts and Figures Revealed

Prime Biome Reviews Controversy Disclosure Report: Surprising Facts and Figures Revealed

ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- In today's fast-paced world, guts and skin health has become a…

2 months ago